Text Size

YKL-40 and Complications in Type 2 Diabetes

This study has been completed.
Sponsor:
Collaborator:
National Science Council, Taiwan
Information provided by:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT01387984
First received: July 1, 2011
Last updated: July 5, 2011
Last verified: June 2011
History of Changes
  Purpose

In this study, the investigators plan to establish the relationship between plasma concentration of YKL-40 with various vascular complications in the patients of type 2 diabetes.


Condition
Type 2 Diabetes Mellitus

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Association Study of the Plasma Concentration of YKL-40 and Vascular Complications in Patients With Type 2 Diabetes

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Taiwan University Hospital:

Enrollment: 473
Study Start Date: April 2010
Study Completion Date: April 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
Type 2 diabetes mellitus

Detailed Description:

It is well recognized now that diabetes mellitus is a systemic vasculopathy and causes various micro- and macrovascular complications. Vascular damage and endothelium dysfunction in diabetes mellitus involve a chronic inflammatory process via a complicated mechanism.

YKL-40 is a 40 kD lectin molecule. It is secreted by various cells, including macrophages, vascular smooth muscle cells and giant cells, and the level of YKL-40 is found elevated in both acute (eg. infection) and chronic (eg. rheumatoid arthritis, systemic lupus erythematosus or cirrhosis of the liver) inflammatory processes. The plasma concentration of YKL-40 is elevated in the patients of type 2 diabetes mellitus compared with non-diabetic controls, and is associated with insulin resistance, fasting plasma glucose and plasma IL-6 concentrations. Furthermore, the concentration of YKL-40 is elevated and is associated with the severity of albuminuria in the patients of type 1 diabetes.

The objective of this study is to establish the relationship between plasma concentration of YKL-40 with various vascular complications in the patients of type 2 diabetes, and to evaluate its potential as a biomarker for the vascular diabetic complications in patients with type 2 diabetes.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

The type 2 diabetic patient who receives follow-up at NTUH diabetics caring network

Criteria

Inclusion Criteria:

  • Clear consciousness
  • type 2 diabetic patient
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01387984

Locations
Taiwan
National Taiwan University Hospital Yun-Lin Branch
Douliu City, Yunlin County, Taiwan, 640
Sponsors and Collaborators
National Taiwan University Hospital
National Science Council, Taiwan
Investigators
Principal Investigator: Chih-Hung Lin, M.D. National Taiwan University Hospital, Yun-Lin Branch
  More Information

No publications provided

Responsible Party: Chih-Hung Lin, MD, National Taiwan University Hospital Yun-Lin Branch
ClinicalTrials.gov Identifier: NCT01387984     History of Changes
Other Study ID Numbers: 201002053R
Study First Received: July 1, 2011
Last Updated: July 5, 2011
Health Authority: Taiwan: Department of Health

Keywords provided by National Taiwan University Hospital:
Type 2 diabetes mellitus
Diabetic complications
YKL-40

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on May 23, 2013